Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972431 | 0.83 | PDE10A (0.44) | PDE10A | |
| SCHEMBL17469574 | 0.77 | KDM4E (0.48) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL28566661 | 0.72 | KDM4E (0.44) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL18597010 | 0.71 | PDE10A (0.46) | PDE10AMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL28566253 | 0.70 | KDM4E (0.43) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL17515540 | 0.67 | KDM4E (0.43) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL25150831 | 0.67 | AKT1 (0.52) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL21316084 | 0.67 | PDE10A (0.47) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL23748001 | 0.66 | KDM4E (0.46) | PDE10AMEN1KMT2AKDM4EAKT1 | |
| SCHEMBL17810209 | 0.66 | PDE10A (0.34) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399985-B2 | (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3099690-B1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399985-B2 | (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders | GRIN2B, MAOB, GRIN2A | PDE10A 3239/4885MEN1 2019/4885KMT2A 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.